Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

about

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

P2860

Q52602960-D3CF1338-007F-4E55-AE9F-4297C98CE86D

P2860

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

Item

http://www.wikidata.org/entity/Q53699940

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Considerations for biomarker-t ...... berculosis disease prevention.

@en

Considerations for biomarker-t ...... berculosis disease prevention.

@nl

type

Item

label

Considerations for biomarker-t ...... berculosis disease prevention.

@en

Considerations for biomarker-t ...... berculosis disease prevention.

@nl

prefLabel

Considerations for biomarker-t ...... berculosis disease prevention.

@en

Considerations for biomarker-t ...... berculosis disease prevention.

@nl

P1476

Considerations for biomarker-t ...... berculosis disease prevention.

@en

P2093

Adam Penn-Nicholson

http://www.w3.org/2001/XMLSchema#string

Andrew Fiore-Gartland

http://www.w3.org/2001/XMLSchema#string

Daniel E Zak

http://www.w3.org/2001/XMLSchema#string

Ethan Thompson

http://www.w3.org/2001/XMLSchema#string

Gavin Churchyard

http://www.w3.org/2001/XMLSchema#string

Lindsay N Carpp

http://www.w3.org/2001/XMLSchema#string

Steve Self

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of latent tuberculosis infection in HIV infected persons

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis

Three months of rifapentine and isoniazid for latent tuberculosis infection

Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure

Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy

The human immune response to tuberculosis and its treatment: a view from the blood

Application of a repeat-measure biomarker measurement error model to 2 validation studies: examination of the effect of within-person variation in biomarker measurements

P304

61-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TUBE.2017.11.009

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29559122

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

biomarker

P932

5884308

http://www.w3.org/2001/XMLSchema#string

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

about

P2860

P2860

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932